Search
M0002
go.drugbank.com/drugs/DB05091InvestigationalIt will be of major benefit to those patients not responding satisfactorily to diuretics alone.
Calusterone
go.drugbank.com/drugs/DB01564ExperimentalIllicitA 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.
LV-SMENP Vaccine
go.drugbank.com/drugs/DB15804ExperimentalLV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which … are based on domains of selected viral proteins.
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with … Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
Alphameprodine
go.drugbank.com/drugs/DB01499ExperimentalIllicitAlphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. … The stereoisomer betameprodine is similarly classified, however alphameprodine is more widely used (both are referred to as Meprodine). Alphameprodine is a structural analogue of meperidine.
Betameprodine
go.drugbank.com/drugs/DB01552ExperimentalIllicitBetameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. … The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
AGA2115
go.drugbank.com/drugs/DB17840InvestigationalDeveloped by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]
Agatolimod
go.drugbank.com/drugs/DB15018InvestigationalAgatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).